Stories
Sai Life Sciences CFO Reveals Growth Plan After Stock Dips 10% From Record High
C
CNBC TV18•30-09-2026, 11:15
Sai Life Sciences CFO Reveals Growth Plan After Stock Dips 10% From Record High
- •Sai Life Sciences, a Hyderabad-based pharma and biotech firm, has seen its stock more than double since listing but recently declined 10% from its record high of ‘1,697.
- •CFO Sivaramakrishnan Chittor projects the company will grow 15–20% over the next three to five years, a significant opportunity for long-term investors.
- •Despite a Q1 profitability dip (27% margin vs. 28–30% guidance), the company expects margins to improve in H2 as revenue increases.
- •Sai Life Sciences is expanding manufacturing capacity and service capabilities, including new facilities for peptides and antibody-drug conjugates (ADCs).
- •The company aims to attract large international drug makers looking to diversify outside China, with drug discovery accounting for 35% of total revenue.
Key Questions Answered
According to Chief Financial Officer Sivaramakrishnan Chittor, Sai Life Sciences is expected to continue growing at a rate of 15–20% over the next three to five years.
The stock declined about 10% from its record high of ₹1,697 primarily due to disappointment in first-quarter profitability, as the company reported a 27% margin that fell below its medium-term guidance of 28–30%.
Sai Life Sciences is expanding into complex drug modalities like peptides and antibody-drug conjugates, with a pilot-scale peptide facility expected by the end of the current financial year or early next year and a larger commercial facility planned for 2028.
